Avantor, Inc. (AVTR)

The stock has dropped 30.3% and now trades at $7.66, rattling many shareholders. This might have investors contemplating their next move. Is now the time to buy Avantor, or should you be careful about including it in your portfolio? Get the full breakdown from our expert analysts, it’s free. Despite…

Avantor stock triggered by recent price slide Avantor (AVTR) has attracted closer attention after its share price fell about 10% over the past month and roughly 18% in the past 3 months, against a backdrop of continued profitability challenges. See our latest analysis for Avantor.

If you are wondering whether Avantor's current share price reflects its underlying value, the recent returns data give you plenty to think about before making any decisions. The stock last closed at US$7.88 and has inched up 0.1% over the past week, but is down 7.3% over 30 days, 31.2% year ...

Longleaf Partners, managed by Southeastern Asset Management, released its first-quarter 2026 investor letter. A copy of the letter is available to download here. The Fund returned -4.46% in the quarter, compared to the S&P 500’s -4.33% and the Russell 1000 Value Index’s 2.10% return.

AVTR currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space that are expected to report earnings soon are DexCom, Inc. DXCM, Encompass Health Corporation EHC and The Cooper Companies, Inc.